A5005119542- Eosinophilic Esophagitis
- Eosinophilic Disorders and Syndromes
- IL-33, ST2, and ILC Pathways
- Inflammatory Bowel Disease
- Microscopic Colitis
- Esophageal and GI Pathology
- Gastroesophageal reflux and treatments
- Autoimmune and Inflammatory Disorders
- Gastrointestinal disorders and treatments
- Liver Diseases and Immunity
- Food Allergy and Anaphylaxis Research
- Autoimmune and Inflammatory Disorders Research
- Immunodeficiency and Autoimmune Disorders
- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal Bleeding Diagnosis and Treatment
- Celiac Disease Research and Management
- Pharmaceutical studies and practices
- Complementary and Alternative Medicine Studies
- Foreign Body Medical Cases
- Mycobacterium research and diagnosis
- Biosimilars and Bioanalytical Methods
- Gastrointestinal motility and disorders
- Tracheal and airway disorders
- Mast cells and histamine
- Psychology, Coaching, and Therapy
University Hospital of Zurich
2017-2025
University of Zurich
2019-2025
Swiss Paediatric Oncology Group
2014-2021
Research Network (United States)
2013-2021
Northwestern University
2018
Mayo Clinic
2017
WinnMed
2017
University Hospital of Basel
2007-2016
Praxis
2005-2016
University of Basel
2012-2015
<h3>Objective:</h3> Eosinophilic oesophagitis (EoO) is a clinicopathological condition defined by proton pump inhibitor-refractory oesophageal symptoms combined with eosinophilia. The pharmacodynamic effect of mepolizumab (a humanised anti-interleukin-5 monoclonal antibody) in EoO was evaluated. <h3>Methods:</h3> Eleven adults active (>20 peak eosinophil number/high power field (hpf) and dysphagia) were randomised to 750 mg (n = 5) or placebo 6) received two intravenous infusions, 1 week...
Studies evaluating the correlation between widely used Simple Endoscopic Score for Crohn's disease (SES-CD) and noninvasive markers are scarce. The aim of this study was to evaluate SES-CD fecal calprotectin, C-reactive protein (CRP), blood leukocytes, activity index (CDAI).Crohn's patients undergoing complete ileocolonoscopy were prospectively enrolled scored independently according CDAI. defined as follows: inactive 0-3; mild 4-10; moderate 11-19; high > or =20.Values in CD (n=140...
Esophageal dilation often leads to long-lasting relief of dysphagia in eosinophilic esophagitis (EoE). The aim this study was define the effectiveness, safety, and patient acceptance esophageal EoE. In addition, we examined influence on underlying inflammation.Two databases including 681 EoE patients were reviewed. Cohort 1 consisted treated with alone, whereas cohort 2 included a combination antieosinophilic medication. Patients from underwent prospective histological reexamination an...
The accuracy of noninvasive markers for the detection endoscopically active ulcerative colitis (UC) according Rachmilewitz Score is so far unknown. aim was to evaluate correlation between endoscopic disease activity and fecal calprotectin, Clinical Activity Index, C-reactive protein (CRP), blood leukocytes.UC patients undergoing colonoscopy were prospectively enrolled scored independently clinical part Index. Patients controls provided samples measuring CRP, leukocytes.Values in UC (n = 134)...
Consensus diagnostic recommendations to distinguish GORD from eosinophilic oesophagitis (EoE) by response a trial of proton pump inhibitors (PPIs) unexpectedly uncovered an entity called 'PPI-responsive oesophageal eosinophilia' (PPI-REE). PPI-REE refers patients with clinical and histological features EoE that remit PPI treatment. Recent evolving evidence, mostly adults, shows at baseline are clinically, endoscopically histologically indistinguishable have significant overlap in terms Th2...
BackgroundThe correlation between noninvasive markers with endoscopic activity according to the modified Baron Index in patients ulcerative colitis (UC) is unknown. We aimed evaluate and fecal calprotectin (FC), C-reactive protein (CRP), hemoglobin, platelets, blood leukocytes, Lichtiger (clinical score).
BackgroundData evaluating the chronological order of appearance extraintestinal manifestations (EIMs) relative to time inflammatory bowel disease (IBD) diagnosis is currently lacking. We aimed assess type, frequency, and EIMs in patients with IBD.
Background & AimsSwallowed topical-acting corticosteroids are recommended as first-line therapy for eosinophilic esophagitis (EoE). Asthma medications not optimized esophageal delivery sometimes effective, although given off-label. We performed a randomized, placebo-controlled trial to assess the effectiveness and tolerability of budesonide orodispersible tablet (BOT), which allows drug be delivered esophagus in adults with active EoE.MethodsWe double-blind, parallel study 88 EoE Europe....
The diagnosis of inflammatory bowel disease (IBD), comprising Crohn's (CD) and ulcerative colitis (UC), continues to present difficulties due unspecific symptoms limited test accuracies. We aimed determine the diagnostic delay (time from first IBD diagnosis) identify associated risk factors. A total 1591 patients (932 CD, 625 UC, 34 indeterminate colitis) Swiss cohort study (SIBDCS) were evaluated. SIBDCS collects data on a large sample hospitals private practice across Switzerland through...
Eosinophilic esophagitis (EoE) is a chronic, esophageal, type 2 inflammatory response associated with increased serum levels of interleukin 13 (IL13), which might contribute to its pathogenesis. RPC4046, recombinant humanized monoclonal antibody against IL13, prevents binding the receptor subunits IL13RA1 and IL13RA2. We performed phase trial evaluate efficacy safety RPC4046 in patients EoE.